Skip to main content

You are here:

VAY736 Study

Phase II study looking at the efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis. It is hoped in this double-blind study to assess the safety of VAY736 and if it has beneficial effects in people who have idiopathic pulmonary fibrosis. The purpose of this study is to determine if VAY736 will improve Lung function.

Study Title

A subject, investigator and sponsor blinded randomised placebo-controlled, multicentre study to investigate efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis.

Eligibility Criteria

A diagnosis of IPE confirmed by HRCT and/or Lung biopsy using the ATS/ERS guidelines.

Therapeutic Area
Respiratory Medicine
Type of Study
Phase II Clinical trial, which is subject, sponsor and investigator blinded.
Study Status
Open Recruiting
Sponsor
Novartis
Principal Investigator
Professor Michael Keane
Contact
Carita.bramhill@ucd.ie